One-year intense nutritional counseling results in histological improvement in patients with nonalcoholic steatohepatitis: A pilot study

American Journal of Gastroenterology

Volumn 100, Issue 5, 2005, Pages 1072-1081

  Huang, Mary Ann ^b   Greenson, Joel K ^b   Chao, Cewin ^b   Anderson, Lilian ^b   Peterman, Debra ^b   Jacobson, Jon ^b   Emick, Dawn ^b   Lok, Anna S ^b   Conjeevaram, Hari S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; INSULIN; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD EXAMINATION; BODY FAT; BODY WEIGHT; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; COUNSELING; DIETARY INTAKE; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER BIOPSY; LIVER HISTOLOGY; MALE; NONALCOHOLIC FATTY LIVER; NUTRITION; NUTRITIONAL COUNSELING; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; ADIPOSE TISSUE; BIOPSY; BLOOD; BODY COMPOSITION; BODY MASS; COMPARATIVE STUDY; DIET THERAPY; EDUCATION; FATTY LIVER; FOLLOW UP; HEPATITIS; HOMEOSTASIS; INTERVENTION STUDY; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY;

ADIPOSE TISSUE; ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOPSY; BLOOD GLUCOSE; BODY COMPOSITION; BODY MASS INDEX; COUNSELING; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; HEPATITIS; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; INTERVENTION STUDIES; MALE; MIDDLE AGED; NUTRITION PHYSIOLOGY; PILOT PROJECTS; PROSPECTIVE STUDIES; TRIGLYCERIDES; WEIGHT LOSS;

EID: 19144372447     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.41334.x     Document Type: Article

References (25)

1. Kumar KS, Malet PF. Nonalcoholic steatohepatitis. Mayo Clin Proc 2000;75(7):733-9.
2. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997;126(2):137-45.
3. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto un-named disease. Mayo Clin Proc 1980;55(7):434-8.
4. Marrero JA, Fontana RJ, Su GL, et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002;36(6):1349-54.
5. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999;116(6):1413-9.
6. Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11(1):74-80.
7. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35(2):373-9.
8. Pagano G, Pacini G, Musso G, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association. Hepatology 2002;35(2):367-72.
9. Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: Effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998;22(3):222-6.
10. Wang RT, Koretz RL, Yee HF, Jr. Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. Am J Med 2003;115(7):554-9.
11. Ranlov I, Hardt F. Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity. Digestion 1990;47(4):208-14.
12. Andersen T, Gluud C, Franzmann MB, et al. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991;12(2):224-9.
13. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27(1):103-7.
14. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-aamma ligand rosiglitazone. Hepatology 2003;38(4):1008-17.
15. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39(1):188-96.
16. Reaven GM. Do high carbohydrate diets prevent the development or attenuate the manifestations (or both) of syndrome X? A viewpoint strongly against. Curr Opin Lipidol 1997;8(1):23-7.
17. Pouliot MC, Despres JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: Best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994;73(7):460-8.
18. Katznelson L, Rosenthal DI, Rosol MS, et al. Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism. Am J Roentgenol 1998;170(2):423-7.
19. Kugelmas M, Hill DB, Vivian B, et al. Cytokines and NASH: A pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003;38(2):413-9.
20. Hickman IJ, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004;53(3):413-9.
21. Caldwell SH, Hespenheide EE, Redick JA, et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96(2):519-25.
22. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393-403.
23. Goodpaster BH, Kelley DE, Wing RR, et al. Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes 1999;48(4):839-47.
24. Ross R, Dagnone D, Jones PJ, et al. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med 2000;133(2):92-103.
25. Ross R, Janssen I. Physical activity, total and regional obesity. Dose-response considerations. Med Sci Sports Exerc 2001;33(6 Suppl):S521-7 (Discussion S528-9).